Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC102 vs Oral Steroids in Idiopathic Sudden Sensorineural Hearing Loss
NCT05776459Phase 2Completed
- Sponsor
- AudioCure Pharma GmbH
- Start
- Oct 2022
- Primary completion
- Nov 2025
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of AC102 in idiopathic sudden sensorineural hearing loss (ISSNHL), sponsored by AudioCure Pharma GmbH. Started Oct 2022; status: completed.
02
Drugs
AC102
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NCT05776459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776459.